| Colorectal Cancer |
1 |
1 |
| Biologic Therapy |
0 |
1 |
| Humanized Monoclonal Antibody |
0 |
1 |
| Genomic Medicine |
0 |
0.6 |
| Angiogenesis Inhibitors |
0 |
0.59 |
| Tumor |
0 |
0.47 |
| Chemotherapy |
0 |
0.35 |
| Epidermal Growth Factor Receptor |
0 |
0.34 |
| Cancer |
0 |
0.32 |
| Combination Chemotherapy |
0 |
0.28 |
| EGFR Inhibitor |
0 |
0.27 |
| Gastrointestinal Cancer |
0 |
0.25 |
| Vascular Endothelial Growth Factor |
0 |
0.2 |
| Monoclonal Antibody |
0 |
0.16 |
| Biomarker |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Melanoma |
0 |
0.09 |
| BRAF |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Biomedical Technology |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Face |
0 |
0.04 |
| Immunotherapy |
0 |
0.04 |
| Intravenous |
0 |
0.04 |
| KRAS |
0 |
0.04 |
| Medical Oncology |
0 |
0.04 |
| Microsatellite Instability |
0 |
0.04 |
| Plasma |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Resection |
0 |
0.04 |
| Tissue |
0 |
0.04 |